Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 17/20 | 0.50 |
| ▸ | RPS6KA2 | Q15349 | 5/20 | 0.42 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.41 |
| ▸ | RPS6KA6 | Q9UK32 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5220213 | 1.00 | RPS6KA3 (0.50) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL5217423 | 0.82 | RPS6KA3 (0.46) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL5762599 | 0.80 | RPS6KA3 (0.56) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL18573359 | 0.79 | RPS6KA3 (0.50) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL5219739 | 0.77 | RPS6KA3 (0.46) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL4043958 | 0.77 | RPS6KA2 (0.48) | RPS6KA3RPS6KA2 | |
| SCHEMBL4043954 | 0.77 | RPS6KA2 (0.48) | RPS6KA3RPS6KA2 | |
| SCHEMBL19252841 | 0.75 | RPS6KA3 (0.53) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL5389081 | 0.75 | RPS6KA3 (0.53) | RPS6KA3RPS6KA2RPS6KA1RPS6KA6 | |
| SCHEMBL4043684 | 0.74 | RPS6KA3 (0.45) | RPS6KA3RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208494-B2 | 5HT2c receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050026925-A1 | 5HT2c receptor agonists | HOFFMANN-LA ROCHE INC. | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026925-A1 | 5HT2c receptor agonists | HTR2C, HTR2A, HTR5A | RPS6KA3 1773/4885RPS6KA2 1443/4885RPS6KA1 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.